MedTrace Logo

DUAL Antithrombotic Therapy in Patients With AF and ACS

NCT04023630 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4000

Last updated 2019-07-17

No results posted yet for this study

Summary

The study aims to show inferiority of rivaroxaban plus ticagrelor when compared to rivaroxaban plus clopidogrel in terms of safety. Safety will be determined by comparing the rates of death or ischemic event-including myocardial infarction, definite or probable stent thrombosis, stroke, or urgent revascularization.

Conditions

Interventions

DRUG

Rivaroxaban 15 MG Oral Tablet

One 15 mg tablet once daily for up to twelve months

DRUG

Clopidogrel 75 Mg Oral Tablet

One 75 mg tablet once daily for up to twelve months

DRUG

Ticagrelor 90 MG Oral Tablet

One 90 mg tablet twice daily for up to twelve months

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Jun Jiang, PhD · Second Affiliated Hospital Zhejiang University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-09-30
Completion
2021-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04023630 on ClinicalTrials.gov